Clinical pharmacokinetics of cannabinoids

The Handbook of Cannabis Therapeutics: From Bench to Bedside

Volumn , Issue , 2014, Pages 69-116

  Grotenhermen, Franjo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85118362552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1300/5741_08     Document Type: Chapter

References (166)

1. Abrams, R.M., C.E. Cook, K.H. Davis, K. Niederreither, M.J. Jaeger, and H.H. Szeto. 1985-1986. Plasma delta-9-tetrahydrocannabinol in pregnant sheep and fetus after inhalation of smoke from a marijuana cigarette. Alcohol Drug Res 6(5):361-369.
2. Agurell, S., S. Carlsson, J.E. Lindgren, A. Ohlsson, H. Gillespie, and L. Hollister. 1981. Interactionsofdelta1-tetrahydrocannabinolwith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37(10):1090-1092.
3. Agurell, S., and K. Leander. 1971. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8(4):391-402.
4. Agurell, S., I.M. Nilsson, A. Ohlsson, and F. Sandberg. 1970. On the metabolism of tritium-labelled, Δ1-tetrahydrocannabinol in the rabbit. Biochem Pharmacol 19(4):1333-1339.
5. Alburges, M.E., and M.A. Peat. 1986. Profiles of delta 9-tetrahydrocannabinol metabolites in urine of marijuana users: preliminary observations by high performance liquid chromatography-radioimmunoassay. J Forensic Sci 31(2):695-706.
6. Alozie, S.O., B.R. Martin, L.S. Harris, and W.L. Dewey. 1980. 3H-delta 9-tetra-hydrocannabinol, 3H-cannabinol and 3H-cannabidiol: Penetration and regional distribution in rat brain. Pharmacol Biochem Behav 12(2):217-221.
7. Bailey, J.R., H.C. Cunny, M.G. Paule, and W. Slikker Jr. 1987. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90(2):315-321.
8. Baker, P.B., B.J. Taylor, and T.A. Gough. 1981. The tetrahydrocannabinol and tetrahydrocannabinolic acid content of cannabis products. J Pharm Pharmacol 33(6): 369-372.
9. Barnett, G., C.W. Chiang, M. Perez-Reyes, and S.M. Owens. 1982. Kinetic study of smoking marijuana. J Pharmacokinet Biopharm 10(5):495-506.
10. Barnett, G., V. Licko, and T. Thompson. 1985. Behavioral pharmacokinetics of marijuana. Psychopharmacology 85(1):51-56.
11. Blackard, C., and K. Tennes. 1984. Human placental transfer of cannabinoids. N Engl J Med 311(12):797.
12. Bornheim, L.M., E.T. Everhart, J. Li, and M.A. Correia. 1994. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 48(1):161-171.
13. Bornheim, L.M., and M.P. Grillo. 1998. Characterization of cytochrome P450 3A inactivation by cannabidiol: Possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 11(10):1209-1216.
14. Bornheim, L.M., K.Y. Kim, J. Li, B.Y. Perotti, and L.Z. Benet. 1995. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23(8):825-831.
15. Borys, H.K., and R. Karler. 1979. Cannabidiol and delta 9-tetrahydrocannabinol metabolism. In vitro comparison of mouse and rat liver crude microsome preparations. Biochem Pharmacol 28(9):1553-1559.
16. Boskovic, R., J. Klein, C. Woodland, T. Karaskov, and G. Koren. 2001. The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: A twin study. Can J Physiol Pharmacol 79(11):942-945.
17. Brenneisen, R. 1984. Psychotrope Drogen. II. Bestimmung der Cannabinoide in Cannabis sativa L. und in Cannabisprodukten mittels Hochdruckflüssigkeitschromatographie (HPLC). Pharmaceutica Acta Helvetiae 59(9-10):247-259.
18. Brenneisen, R. 2002. Pharmacokinetics. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 67-72). Binghamton, NY: The Haworth Press, Inc.
19. Brenneisen, R., A. Egli, M.A. Elsohly, V. Henn, and Y. Spiess. 1996. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J Clin Pharmacol Ther 34(10):446-452.
20. Brewster, M.E., E. Pop, R.L. Foltz, S. Reuschel, W. Griffith, S. Amselem, and A. Biegon. 1997. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int JClin Pharmacol Ther 35(9):361-365.
21. Chao, F.C., D.E. Green, I.S. Forrest, J.N. Kaplan, A. Winship-Ball, and M. Braude. 1976. The passage of 14C-delta-9-tetrahydrocannabinol into the milk of lactating squirrel monkeys. Res Commun Chem Pathol Pharmacol 15(2):303-317.
22. Chiang, C.W., and G. Barnett. 1984. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther 36(2):234-238.
23. Chiang, C.W., G. Barnett, and D. Brine. 1983. Systemic absorption of delta 9-tetrahydrocannabinol after ophthalmic administration to the rabbit. J Pharm Sci 72(2): 136-138.
24. Chiang, C.N., and R.S. Rapaka. 1987. Pharmacokinetics and disposition of cannabinoids. NIDA Res Monogr 79:173-188.
25. Cocchetto, D.M., S.M. Owens, M. Perez-Reyes, S. DiGuiseppi, and L.L. Miller. 1981. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 75(2):158-164.
26. Cone, E.J., and M.A. Huestis. 1993. Relating blood concentrations of tetrahydro-cannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 15(6):527-532.
27. Cone E.J., and R.E. Johnson. 1986. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther 40(3):247-256.
28. Cone, E.J., R.E. Johnson, W.D. Darwin, D. Yousefnejad, L.D. Mell, B.D. Paul, and J. Mitchell. 1987. Passive inhalation of marijuana smoke: Urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 11(3):89-96.
29. Consroe, P., J. Laguna, J. Allender, S. Snider, L. Stern, R. Sandyk, K. Kennedy, and K. Schram. 1991. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40(3):701-708.
30. Costa, B., D. Parolaro, and M. Colleoni. 1996. Chronic cannabinoid, CP-55, 940, administration alters biotransformation in the rat. Eur J Pharmacol 313(1-2):17-24.
31. Daldrup, Th. 1996. Cannabis im Straßenverkehr. Final report commissioned by the Ministry of Economy, Technology and Traffic of North Rhine-Westphalia. Düsseldorf: University of Düsseldorf.
32. Daldrup, Th., T. Thompson, and G. Reidenbach. 1988. Cannabiskonsum-Nachweisbarkeitsdauer, zeitlicher Verlauf, forensische Bedeutung. In W. Arnold, W.E. Poser, and M.R. Möller (eds.), Suchtkrankheiten, Diagnose, Therapie und analytischer Nachweis (pp. 39-51). Berlin, Heidelberg: Springer-Verlag.
33. Davis, K.H., J.A. McDaniell, L.W. Cadwell, and P.L. Moody. 1984. Some smoking characteristics of marijuana cigarettes. In S. Agurell, W.L. Dewey, and R.E. Willette (eds.), The cannabinoids: Chemical, pharmacologic and therapeutic aspects (pp. 245-261). New York: Academic Press.
34. Dewey, W.L. 1986. Cannabinoid pharmacology. Pharmacol Rev 38(2):151-178.
35. Ellis, G.M. Jr., M.A. Mann, B.A. Judson, N.T. Schramm, and A. Tashchian. 1985. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38(5):572-578.
36. ElSohly, M.A. 2002. Chemical constituents of cannabis. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential (pp. 27-36). Binghamton, NY: The Haworth Press, Inc.
37. 9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45(1):24-30.
38. ElSohly, M.A., D.F. Stanford, E.C. Harland, A.H. Hikal, L.A. Walker, T.L. Little Jr., J.N. Rider, and A.B. Jones. 1991. Rectal bioavailability of delta-9-tetrahydro-cannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 80(10):942-945.
39. Fairbairn, J.W., J.A. Liebmann, and M.G. Rowan. 1976. The stability of cannabis and its preparations on storage. J Pharm Pharmacol 28(1):1-7.
40. Fehr, K.O., and H. Kalant. 1974. Fate of 14C-delta1-THC in rat plasma after intravenous injection and smoking. Eur J Pharmacol 25(1):1-8.
41. Frytak, S., C.G. Moertel, and J. Rubin. 1984. Metabolic studies of delta-9-tetra-hydrocannabinol in cancer patients. Cancer Treat Rep 68(12):1427-1431.
42. 9-tetrahydrocannabinol. J Pharm Sci 63(7):1056-1064.
43. Garriott, J.C., V.J. Di Maio, and R.G. Rodriguez. 1986. Detection of cannabinoids in homicide victims and motor vehicle fatalities. J Forensic Sci 31(4):1274-1282.
44. Gill, E.W., and G. Jones. 1972. Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice-correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 21(16):2237-2248.
45. Gronholm, M., and P. Lillsunde. 2001. A comparison between on-site immunoassay drug-testing devices and laboratory results. Forensic Sci Int 121(1-2):37-46.
46. Grotenhermen, F. 2001. Grenzwertmodelle zur Bestimmung der Fahrtüchtigkeit und Messverfahren. In F. Grotenhermen and M. Karus (eds.), Cannabiskonsum, Straßenverker und Arbeitswelt [Cannabis use, driving and workplace] (pp. 313-344). Heidelberg: Springer-Verlag.
47. Grotenhermen, F. 2002a. Practical hints. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 345-353). Binghamton, NY: The Haworth Press, Inc.
48. Grotenhermen, F. 2002b. Review of unwanted actions of Cannabis and THC. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 233-247). Binghamton, NY: The Haworth Press, Inc.
49. Grotenherman, F. 2002c. IAMC Bulletin, March 3. http://www.cannabis-med.org/english/nav/home-bulletin.htm.
50. Guy, G.W., and M.E. Flint. 2000. A phase one study of sublingual Cannabis based medicinal extracts. 2000 Symposium on the Cannabinoids, Burlington, VT: International Cannabinoid Research Society, p. 115.
51. Haggerty, G.C., R. Deskin, P.J. Kurtz, A.F. Fentiman, and E.G., Leighty. 1986. The pharmacological activity of the fatty acid conjugate 11-palmitoyloxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol 84(3):599-606.
52. Halldin, M.M., L.K. Andersson, M. Widman, and L.E. Hollister. 1982. Further urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittelforschung 32(9):1135-1138.
53. Halldin, M.M., S. Carlsson, S.L. Kanter, M. Widman, and S. Agurell. 1982. Urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittelforschung 32(7): 764-768.
54. 9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 7(2):96-102.
55. Harder, S., and S. Rietbrock. 1997. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 35(4):155-159.
56. Harvey, D.J. 1976. Characterization of the butyl homologues of delta1-tetrahydro-cannabinol, cannabinol and cannabidiol in samples of cannabis by combined gas chromatography and mass spectrometry. J Pharm Pharmacol 28(4):280-285.
57. Harvey, D.J. 1984. Chemistry, metabolism and pharmacokinetics of the cannabinoids. In G. Nahas (ed.), Marihuana in Science and Medicine (pp. 37-107). New York: Raven Press.
58. Harvey, D.J. 1991. Metabolism and pharmacokinetics of the cannabinoids. In R.R. Watson (ed.), Biochemistry and Physiology of Substance Abuse (pp. 279-295), Volume III. Boca Raton, FL: CRC Press.
59. Harvey, D.J., and N.K. Brown. 1991. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 40(3):533-540.
60. Harvey, D.J., J.T. Leuschner, and W.D. Paton. 1982. Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. J Chromatogr 239:243-250.
61. Harvey, D.J., and R. Mechoulam. 1990. Metabolites of cannabidiol identified in human urine. Xenobiotica 20(3):303-320.
62. Harvey, D.J., and W.D.M. Paton. 1976. Examination of the metabolites of Δ1-tetrahydrocannabinol in mouse, liver, heart and lung by combined gas chromatography and mass spectrometry. In G.G. Nahas (ed.), Marihuana: Chemistry, Biochemistry and Cellular Effects (pp. 93-109). New York: Springer-Verlag.
63. Ho, B.T., G.E. Fritchie, P.M. Kralik, L.F. Englert, W.M. McIsaac, and J. Idanpaan-Heikkila. 1970. Distribution of tritiated-1 delta 9-tetrahydrocannabinol in rat tissues after inhalation. J Pharm Pharmacol 22(7):538-539.
64. Hollister, L.E. 1974. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology11(1):3-11.
65. Hollister, L.E., and H. Gillespie. 1975. Interactions in man of delta-9-tetrahydro-cannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther 18(1):80-83.
66. Hollister, L.E., H.K. Gillespie, A. Ohlsson, J.E. Lindgren, A. Wahlen, and S. Agurell. 1981. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 21(8-9 Suppl):171S-177S.
67. 9-tetrahydrocannabinol in humans. Ther Drug Monit 20(5):570-576.
68. Huestis, M.A., J.E. Henningfield, and E.J. Cone. 1992a. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16(5):276-282.
69. Huestis, M.A., J.E. Henningfield, E.J. Cone. 1992b. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydro-cannabinol (THCCOOH). J Anal Toxicol 16(5):283-290.
70. Hunt, C.A. and R.T. Jones. 1980. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215(1):35-44.
71. Hunt, C.A., R.T. Jones, R.I. Herning, and J. Bachman. 1981. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9(3):245-260.
72. Hutchings, D.E., B.R. Martin, Z. Gamagaris, N. Miller, and T. Fico. 1989. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 44(11):697-701.
73. Jaeger, W., L.Z. Benet, and L.M. Bornheim. 1996. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26(3):275-284.
74. Johansson, E., and M.M. Halldin. 1989. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13(4):218-223.
75. Johansson, E., M.M. Halldin, S. Agurell, L.E. Hollister, and H.K. Gillespie. 1989. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 37(3):273-277.
76. Johansson, E., K. Noren, J. Sjovall, and M.M. Halldin. 1989. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3(1):35-38.
77. Johansson, E., A. Ohlsson, J.E. Lindgren, S. Agurell, H. Gillespie, and L.E. Hollister. 1987. Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 14(9): 495-499.
78. Johnson, J.R., T.A. Jennison, M.A. Peat, and R.L. Foltz. 1984. Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 8(5):202-204.
79. Karniol, I.G., I. Shirakawa, N. Kasinski, A. Pfeferman, and E.A. Carlini. 1974. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28(1):172-177.
80. Kelly, T.H., R.W. Foltin, C.S. Emurian, and M.W. Fischman. 1993. Performance-based testing for drugs of abuse: Dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 17(5):264-272.
81. Kelly, P., and R.T. Jones. 1992. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16(4):228-235.
82. Kintz, P., V. Cirimele, and B. Ludes. 2000. Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 24(7): 557-561.
83. Kommission Deutscher Arzneimittel-Codex. 2001. Monograph: Dronabinol. In Deutscher Arzneimittel-Codex (DAC), Loose-Leaf Collection of 2001, edited by Bundesvereinigung Deutscher Apothekerverbände. Eschborn, Germany: Govi-Verlag Pharmazeutischer Verlag/Stuttgart, Germany: Deutscher ApothekerVerlag.
84. Kosel, B.W., F.T. Aweeka, N.L. Benowitz, S.B. Shade, J.F. Hilton, P.S. Lizak, and D.I. Abrams. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16(4):543-550.
85. Kreuz, D.S., and J. Axelrod. 1973. Delta-9-tetrahydrocannabinol: localization in body fat. Science 179 (71):391-393.
86. Law, B., P.A. Mason, A.C. Moffat, R.I. Gleadle, and L.J. King. 1984. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36(5):289-294.
87. Law, B., and A.C. Moffat. 1985. In D.J. Harvey (ed.), Marijuana '84 (pp. 197-204). Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited.
88. Leighty, E.G., 1973. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 22(13):1613-1621.
89. 8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 14(1):13-28.
90. Lemberger, L., A. Rubin, R. Wolen, K. DeSante, H. Rowe, R. Forney, and P. Pence. 1982. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9(Suppl B):17-23.
91. Lemberger, L., S.D. Silberstein, J. Axelrod, and I.J. Kopin. 1970. Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170(964):1320-1322.
92. Lemberger, L., N.R. Tamarkin, J. Axelrod, and I.J. Kopin. 1971. Delta-9-tetra-hydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173(991):72-74.
93. Lemberger, L., J.L. Weiss, A.M. Watanabe, I.M. Galanter, R.J. Wyatt, and P.V. Cardon. 1972. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med 286(13):685-688.
94. Leuschner, J.T., D.J. Harvey, R.E. Bullingham, and W.D. Paton. 1986. Pharmaco-kinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metab Dispos 4(2):230-238.
95. Lichtman, A.H., J. Peart, J.L. Poklis, D.T. Bridgen, R.K. Razdan, D.M. Wilson, A. Poklis, Y. Meng, P.R. Byron, B.R. Martin. 2000. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 399(2-3):141-149.
96. Lindgren, J.E., A. Ohlsson, S. Agurell, L. Hollister, H. Gillespie. 1981. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74(3):208-212.
97. Magerl, H., C. Wiegand, E. Schulz. 1987. Cannabinoid-Aufnahme durch Passivrauchen. Arch Kriminol 179(1-2):31-37.
98. Manno, J.E., B.R. Manno, P.M. Kemp, D.D. Alford, I.K. Abukhalaf, M.E. McWil-liams, F.N. Hagaman, and M.J. Fitzgerald. 2001. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Δ9-tetra-hydrocannabinol, 11-hydroxy-Δ 9-tetrahydrocannabinol, and 11-nor-Δ 9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25(7):538-549.
99. Martin, B.R., W.L. Dewey, L.S. Harris, and J.S. Beckner. 1977. 3H-delta 9-tetra-hydrocannabinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 17: 457-470.
100. Matsunaga, T., Y. Iwawaki, K. Watanabe, I. Yamamoto, T. Kageyama, and H. Yoshimura. 1995. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 56(23-24): 2089-2095.
101. McBurney, L.J., B.A. Bobbie, and L.A. Sepp. 1986. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 10(2):56-64.
102. McIsaac, W., G. Fritchie, J. Idanpaan-Heikkila, B. Ho, and L. Englert. 1971. Distribution of marihuana in monkey brain and concomitant behavioural effects. Nature 230(5296):593-594.
103. McLeod, A.L., C.J. McKenna, and D.B. Northridge. 2002. Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin Cardiol 25(3): 133-134.
104. Mechoulam, R. 1981. Chemistry of cannabis. Handbook Exp Pharmacol 53:119-134.
105. Merritt, J.C., J.L. Olsen, J.R. Armstrong, and S.M. McKinnon. 1981. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 33(1): 40-41.
106. Mikes, F., A. Hofmann, and P.G. Waser. 1971. Identification of (-)-delta 9-6a,10a-trans-tetrahydrocannabinol and two of its metabolites in rats by use of combination gaschromatography-mass spectrometry and mass fragmentography. Biochem Pharmacol 20(9): 2469-2476.
107. Mittleman, M.A., R.A. Lewis, M. Maclure, J.B. Sherwood, and J.E. Muller. 2001. Triggering myocardial infarction by marijuana. Circulation 103(23):2805-2809.
108. Mule, S.J., P. Lomax, and S.J. Gross. 1988. Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine. J Anal Toxicol 12(3): 113-116.
109. Mura, P., P. Kintz, Y. Papet, G. Ruesch, and A. Piriou. 1999. Evaluation de six tests rapides pour le depistage du cannabis dans la sueur, la salive et les urines. Acta Clin Belg Suppl 1:35-38.
110. N. N. Monographs. 2001. Dronabinol capsules 2.5 / 5 or 10 mg (NRF 22.7.); oily dronabinol drops 2.5 percent (NRF 22.8). In Deutscher Arzneimittel-Codex (DAC), Loose-Leaf Collection of 2001, edited by Bundesvereinigung Deutscher Apothekerverbände. Eschborn, Germany: Govi-Verlag Pharmazeutischer Verlag/ Stuttgart, Germany: Deutscher Apotheker-Verlag.
111. Nakazawa, K., and E. Costa. 1971. Metabolism of delta-9-tetrahydrocannabinol by lung and liver homogenates of rats treated with methylcholanthrene. Nature 234(5323): 48-49.
112. Narimatsu, S., K. Watanabe, T. Matsunaga, I. Yamamoto, S. Imaoka, Y. Funae, and H. Yoshimura. 1992. Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metab Dispos 20(1):79-83.
113. Niedbala, R.S., K.W. Kardos, D.F. Fritch, S. Kardos, T. Fries, J. Waga, J. Robb, and E.J. Cone. 2001. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 25(5):289-303.
114. Notcutt, W., M. Price, R. Miller, S. Newport, C. Sansom, and S. Simmonds. 2001. Medicinal cannabis extracts in chronic pain: (5) cognitive function and blood cannabinoid levels. 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Association for Cannabis as Medicine, p. 28.
115. Nyoni, E.C., B.R. Sitaram, and D.A. Taylor. 1996. Determination of delta 9-tetrahydrocannabinol levels in brain tissue using high-performance liquid chro-matography with electrochemical detection. J Chromatogr B Biomed Appl 679 (1-2): 79-84.
116. Ohlsson, A., E. Johansson, J.E. Lindgren, S. Agurell, H. Gillespie, and L.E. Hollister. 1985. Kinetics of cannabinol in man. In D.J. Harvey (ed.), Marihuana '85.Oxford: IRL Press.
117. Ohlsson, A., J.E. Lindgren, S. Andersson, S. Agurell, H. Gillespie, and L.E. Hollister. 1984. Single dose kinetics of cannabidiol in man. In S. Agurell, W.L. Dewey, and R. Willette (eds.), The cannabinoids: Chemical, pharmacologic, and therapeutic aspects (pp. 219-225). New York: Academic Press.
118. Ohlsson, A., J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, and H.K. Gil-lespie. 1980. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28(3): 409-416.
119. Ohlsson, A., J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, and H.K. Gillespie. 1982. Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9(1):6-10.
120. Ohlsson, A., M. Widman, S. Carlsson, T. Ryman, and C. Strid. 1980. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol (Copenh) 47(4):308-317.
121. Perez-Reyes, M., S. Di Guiseppi, K.H. Davis, V.H. Schindler, and C.E. Cook. 1982. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 31(5):617-24.
122. Perez-Reyes, M., S. Di Guiseppi, A.P. Mason, and K.H. Davis. 1983. Passive inhalation of marihuana smoke and urinary excretion of cannabinoids. Clin Pharmacol Ther 34(1):36-41.
123. 9-tetra-hydrocannabinol to the brain of mice. In G.G. Nahas (ed.), Marihuana: Chemistry, Biochemistry, and Cellular Effects (pp. 179-187). New York: Springer.
124. Perez-Reyes, M., M. Timmons, M. Lipton, K. Davis, and M. Wall. 1972. Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetra-hydrocannabinol. Science 177(49):633-635.
125. Perez-Reyes, M., and M.E. Wall. 1982. Presence of delta 9-tetrahydrocannabinol in human milk. N Engl J Med 307:819-820.
126. Petitet, F., B. Jeantaud, M. Reibaud, A. Imperato, and M.C. Dubroeucq. 1998. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63(1): PL1-PL6.
127. Pitts, J.E., J.D. Neal, and T.A. Gough. 1992. Some features of Cannabis plants grown in the United Kingdom from, seeds of known origin. J Pharm Pharmacol 44(12): 947-951.
128. Pryor, G.T., S. Husain, and C. Mitoma. 1976. Acute and subacute interactions between delta-9-tetrahydrocannabinol and other drugs in the rat. Ann N Y Acad Sci 281: 171-189.
129. Reid, M.J., and L.M. Bornheim. 2001. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 61(11):1357-1367.
130. Robbe, H.W.J. 1994. Influence of marijuana on driving. Maastricht: Institut for Human Psychopharmacology, University of Limburg.
131. Rubin, A., L. Lemberger, P. Warrick, R.E. Crabtree, H. Sullivan, H. Rowe, and B.D. Obermeyer. 1977. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 22(1):85-91.
132. Ryrfeldt, A., C.H. Ramsay, I.M. Nilsson, M. Widman, and S. Agurell. 1973. Whole-body autoradiography of Δ1-tetrahydrocannabinol and Δ1(6)-tetrahydrocan-nabinol in mouse. Pharmacokinetic aspects of Δ1-tetrahydrocannabinol and its metabolites. Acta Pharm Suec 10(1): 13-28.
133. Samara, E., M. Bialer, and R. Mechoulam. 1988. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 16(3):469-472.
134. Samyn, N., and C. van Haeren. 2000. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med 113(3):150-154.
135. Schwartz, R.H., G.F. Hayden, and M. Riddile. 1985. Laboratory detection of marijuana use. Experience with a photometric immunoassay to measure urinary cannabinoids. Am J Dis Child 139(11):1093-1096.
136. See, G. 1890. Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. Dtsch Med Wschr 60(31-34):679-682, 727-730, 748-754, 771-774.
137. Sporkert, F., F. Pragst, C.J. Ploner, A. Tschirch, and A.M. Stadelmann. 2001. Pharmacokinetic investigation of delta-9-tetrahydrocannabinol and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study with 17 volunteers. Poster at the 39th Annual International Meeting, The International Association of Forensic Toxicologists, Prague, Czech Republic, August 26-30, 62.
138. Steinmeyer, S., H. Ohr, H.J. Maurer, and M.R. Moeller. 2001. Practical aspects of roadside tests for administrative traffic offences in Germany. Forensic Sci Int 121(1-2):33-36.
139. Sticht, G., and H. Käferstein. 1998. Grundbegriffe, Toxikokinetik und Toxiko-dynamik. In G. Berghaus, H.P. Krüger (eds.), Cannabis im Straßenverkehr (p. 1-11). Stuttgart: Gustav Fischer.
140. Stinchcomb, A., P. Challapalli, K. Harris, and J. Browe. 2001. Optimization of in vitro experimental conditions for measuring the percutaneous absorption of Δ9-THC, cannabidiol, and WIN55, 212-2. 2001 Symposium on the Cannabinoids. Burlington Vermont: International Cannabinoid Research Society.
141. Sullivan, H.R., G.K. Hanasono, W.M. Miller, and P.G. Wood. 1987. Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes. Xenobiotica 17(4):459-468.
142. Sullivan, H.R., D.L. Kau, and P.G. Wood. 1978. Pharmacokinetics of nabilone, a psychotropically active 9-ketocannabinoid, in the dog. Utilization of quantitative selected ion monitoring and deuterium labeling. Biomed Mass Spectrom 5(4): 296-301.
143. Thomas, B.F., D.R. Compton, and B.R. Martin. 1990. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 255(2): 624-630.
144. Timpone, J.G., D.J. Wright, N. Li, M.J. Egorin, M.E. Enama, J. Mayers, G. Galetto, and the DATRI 004 Study Group. 1997. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 13(4):305-315.
145. Touitou, E., and B. Fabin. 1988. Altered skin permeation of a highly lipophilic molecule: Tetrahydrocannabinol. Int J Pharm 43:17-22.
146. Touitou, E., B. Fabin, S. Dany, and S. Almog. 1988. Transdermal delivery of tetrahydrocannabinol. Int J Pharm 43: 9-15.
147. Turner, C., M.A. ElSohly, and E. Boeren. 1980. Constituent of Cannabis sativa L. XVII. A review of the natural constituents. Journal of Natural Products 43(2): 169-234.
148. Vree, T.B., D.D. Breimer, C.A. van Ginneken, and J.M. van Rossum. 1972. Identification in hashish of tetrahydrocannabinol, cannabidiol and cannabinol analogues with a methyl side-chain. J Pharm Pharmacol 24(1):7-12.
149. Wachtel, S.R., M.A. ElSohly, S.A. Ross, J. Ambre, and H. De Wit. 2002. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161(4):331-339.
150. Wahlqvist, M., I.M. Nilsson, F. Sandberg, and S. Agurell. 1970. Binding of delta-1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol 19(9): 2579-2584.
151. Wall, M.E. 1971. The in vivo and in vitro metabolism of tetrahydrocannabinol. Ann N Y Acad Sci 191:23-29.
152. Wall, M.E., D.R. Brine, and M. Perez-Reyes. 1976. Metabolism of cannabinoids in man. In M.C. Braude, S. Szara (eds.), Pharmacology of marihuana (pp. 93-113). New York: Raven Press.
153. Wall, M.E., D.R. Brine, C.G. Pitt, and M. Perez-Reyes. 1972. Identification of Δ9-tetrahydrocannabinol and metabolites in man. J Am Chem Soc 94(24): 8579-8581.
154. Wall, M.E., and M. Perez-Reyes. 1981. The metabolism of delta 9-tetrahydro-cannabinol and related cannabinoids in man. J Clin Pharmacol 21(8-9 Suppl): 178S-189S.
155. Wall, M.E., B.M. Sadler, D. Brine, H. Taylor, and M. Perez-Reyes. 1983. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 34(3):352-363.
156. Watanabe, K., M. Arai, S. Narimatsu, I. Yamamoto, and H. Yoshimura. 1986. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the hepatic microsomal drug-metabolizing enzyme system of mice. Biochem Pharmacol 35(11):1861-1865.
157. Watanabe, K., M. Arai, S. Narimatsu, I. Yamamoto, and H. Yoshimura. 1987. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem Pharmacol 36(20):3371-3377.
158. Watanabe, K., T. Matsunaga, I. Yamamoto, Y. Funae, and H. Yoshimura. 1995. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18(8):1138-1141.
159. Widman, M., S. Agurell, M. Ehrnebo, and G. Jones. 1974. Binding of (+)- and (-)-Δ 1-tetrahydrocannabinols and (-)-7-hydroxy-Δ 1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 26(11):914-916.
160. Widman, M., M. Halldin, and B. Martin. 1978. In vitro metabolism of tetrahydrocannabinol by rhesus monkey liver and human liver. Adv Biosci 22-23:101-103.
161. Widman, M., M. Nordqvist, C.T. Dollery, and R.H. Briant. 1975. Metabolism of delta1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 27(11):842-848.
162. Williams, S.J., J.P. Hartley, and J.D. Graham. 1976. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31(6): 720-723.
163. Williams, P.L., and A.C. Moffat. 1980. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: A tetrahydrocannabinol metabolite. J Pharm Pharmacol 32(7):445-448.
164. Yamamoto, I., K. Watanabe, S. Narimatsu, and H. Yoshimura. 1995. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 27(8): 741-746.
165. Zuardi, A.W., I. Shirakawa, E. Finkelfarb, and I.G. Karniol. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245-250.
166. Zullino, D.F., D. Delessert, C.B. Eap, M. Preisig, and P. Baumann. 2002. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17(+3):141-143.